Barclays’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,532
| Closed | -$66 | – | 5004 |
|
|
2025
Q4 | $66 | Sell |
2,532
-2
| -0.1% | – | ﹤0.01% | 5128 |
|
|
2025
Q3 | $330 | Hold |
2,534
| – | – | ﹤0.01% | 5222 |
|
|
2025
Q2 | $608 | Sell |
2,534
-47,534
| -95% | -$12.7K | ﹤0.01% | 5073 |
|
|
2025
Q1 | $9.86K | Buy |
50,068
+7
| +0% | +$4 | ﹤0.01% | 4868 |
|
|
2024
Q4 | $27K | Hold |
50,061
| – | – | ﹤0.01% | 4877 |
|
|
2024
Q3 | $47.6K | Hold |
50,061
| – | – | ﹤0.01% | 4757 |
|
|
2024
Q2 | $48.8K | Hold |
50,061
| – | – | ﹤0.01% | 4219 |
|
|
2024
Q1 | $79.1K | Hold |
50,061
| – | – | ﹤0.01% | 4513 |
|
|
2023
Q4 | $39.7K | Hold |
50,061
| – | – | ﹤0.01% | 4807 |
|
|
2023
Q3 | $39K | Hold |
50,061
| – | – | ﹤0.01% | 3966 |
|
|
2023
Q2 | $46.3K | Buy |
+50,061
| New | +$59.7K | ﹤0.01% | 3875 |
|
|
2022
Q4 | – | Sell |
-340,068
| Closed | -$366K | – | 5257 |
|
|
2022
Q3 | $366K | Buy |
340,068
+87,386
| +35% | +$161K | ﹤0.01% | 2867 |
|
|
2022
Q2 | $430K | Buy |
+252,682
| New | +$434K | ﹤0.01% | 2977 |
|
|
2021
Q4 | – | Sell |
-11
| Closed | – | – | 4094 |
|
|
2021
Q3 | $0 | Sell |
11
-38
| -78% | -$170 | ﹤0.01% | 4723 |
|
|
2021
Q2 | $0 | Sell |
49
-8,140
| -99% | -$39.5K | ﹤0.01% | 4853 |
|
|
2021
Q1 | $43K | Buy |
8,189
+201
| +3% | +$1.15K | ﹤0.01% | 4233 |
|
|
2020
Q4 | $43K | Buy |
7,988
+588
| +8% | +$3.19K | ﹤0.01% | 4469 |
|
|
2020
Q3 | $59K | Hold |
7,400
| – | – | ﹤0.01% | 4509 |
|
|
2020
Q2 | $74K | Hold |
7,400
| – | – | ﹤0.01% | 4712 |
|
|
2020
Q1 | $20K | Buy |
7,400
+6,874
| +1,307% | +$22.8K | ﹤0.01% | 5639 |
|
|
2019
Q4 | $1K | Sell |
526
-1,117
| -68% | -$1.19K | ﹤0.01% | 6262 |
|
|
2019
Q3 | $2K | Buy |
+1,643
| New | +$3.84K | ﹤0.01% | 6535 |
|
|
2019
Q2 | – | Sell |
-871
| Closed | -$4K | – | 6898 |
|
|
2019
Q1 | $4K | Buy |
871
+600
| +221% | +$2.79K | ﹤0.01% | 6736 |
|
|
2018
Q4 | $2K | Buy |
271
+213
| +367% | +$1.57K | ﹤0.01% | 6682 |
|
|
2018
Q3 | $1K | Sell |
58
-35,053
| -100% | -$367K | ﹤0.01% | 6994 |
|
|
2018
Q2 | $417K | Sell |
35,111
-840
| -2% | -$10.5K | ﹤0.01% | 4126 |
|
|
2018
Q1 | $403K | Buy |
35,951
+851
| +2% | +$7.45K | ﹤0.01% | 4181 |
|
|
2017
Q4 | $234K | Sell |
35,100
-2,500
| -7% | -$19.3K | ﹤0.01% | 4562 |
|
|
2017
Q3 | $308K | Buy |
+37,600
| New | +$235K | ﹤0.01% | 4049 |
|
Other funds holding ADAP
Barclays's ADAP Position: Q1 2026 in Review
Barclays sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 2,532 shares — an estimated $66 sold.
Barclays first reported a position in ADAP in Q3 2017 and held it in 29 quarters. The position peaked at $430K in Q2 2022. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Barclays reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Barclays sold 2,532 Adaptimmune Therapeutics shares in Q1 2026, an estimated $66.
- Barclays first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 29 quarters.
- Barclays's Adaptimmune Therapeutics position peaked at $430K in Q2 2022.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.